Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies. Central to their product offerings is the percutaneous hepatic perfusion (PHP) system, which enables targeted delivery of high-dose chemotherapy directly to the liver. This approach aims to maximize impact on cancer cells while minimizing systemic exposure and related side effects. Delcath Systems Inc. operates primarily within the healthcare sector, impacting the medical device and oncology industries. The company engages with hospitals, medical professionals, and patients, contributing to evolving treatment protocols for liver cancer. By developing interventional medical solutions, Delcath Systems Inc. plays a significant role in advancing targeted cancer therapies and enhancing the arsenal of available tools in oncology. Headquartered in New York, the company is part of a growing movement towards personalized and precision medicine, seeking to improve patient outcomes through targeted therapeutic interventions.